Federal award (DELIVERY ORDER, fiscal year 2022)
Recipient: THE INSTITUTE FOR CANCER RESEARCH
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2023-05-03 to 2026-05-02
Current total value of award: $1199274
Description: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS  TASK ORDER TITLE: SULFORAPHANE FOR THE PREVENTION OF MALIGNANT MESOTHELIOMA